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Abstract
Heat shock proteins (HSPs) are molecular chaperones that maintain proteins in their correct conformation to ensure stability
and protect carcinoma cells from apoptosis. HSP90 inhibitors (HSP90i) block multiple targets simultaneously, and despite
responses in a selected population, no HSP90i have yet been approved. We present a patient with a lung tumor with an
exceptional response to cisplatin/gemcitabine in combination with HSP90i, which nowadays continues with HSP90i
maintenance after three years. Whole-exome sequencing of the lung tumor unveiled a BRCA1/2 deficiency mutational signa-
ture, and mutation analysis confirmed a germline BRCA1 mutation. The striking efficacy of HSP90i plus chemotherapy vs che-
motherapy alone was reproduced in a patient-derived xenograft (PDX) model from a breast cancer patient with a BRCA1 mu-
tation (mean tumor volume [SD], No. of tumors: vehicle 8.38 [7.07] mm3, n ¼ 3; HSP90i 4.18 [1.93] mm3, n ¼ 5; cisplatin plus
gemcitabine 3.31 [1.95] mm3, n ¼ 5; cisplatin plus gemcitabine plus HSP90i 0.065 [0.076] mm3, n ¼ 6). This case and the PDX
demonstrate the efficacy for therapeutic inhibition of HSP90 in a BRCA-mutated patient, opening a new potential avenue for
better identifying patients who might benefit most from HSP90i.
BRCA1 is a nuclear tumor suppressor critical for the DNA repair
of double-strand breaks (DSBs) and interstrand-crosslinks (ICL)
by the homologous recombination repair (HRR) mechanism.
Inherited mutations in a BRCA1 gene are associated with an in-
creased risk of developing breast and ovarian cancer by age 70
years (1). Tumors with BRCA1 mutations are sensitive to agents
that induce DNA-DSBs including platinum salts and PARP
inhibitors, but despite initial responses, acquired resistance
develops (2). The overall prevalence of germline BRCA1/2 muta-
tions in cancer patients is not well known and has been
reported in 12% to 15% of ovarian cancers, 5% to 10% of pancre-
atic cancers, 5% of breast cancers, 2% of lung cancers, and 2% of
prostate cancers (3,10).
Here we present the case of a patient diagnosed with non–
small cell lung cancer (NSCLC) carrying a germline BRCA1
(gBRCA1) mutation with an ongoing response to HSP90i
maintenance after cisplatin/gemicitabine plus HSP90i for more
than three years (Figure 1). A female patient age 36 years was di-
agnosed with a hormone receptor–positive invasive ductal
breast carcinoma (IDC) with no evidence of disease after local
and adjuvant therapy (Supplementary Figure 1, available on-
line). Eight years later, the patient was diagnosed with squa-
mous NSCLC T3N0M0. She underwent right pneumonectomy
and lymphadenectomy with a pathologic result of 11.5 cm squa-
mous lung carcinoma with negative hormonal receptors and
lymph nodes. The patient presented a chylothorax with slow
resolution failing to receive adjuvant treatment. Three months
after the pneumonectomy, a computed tomography (CT) scan
showed liver metastasis. A hepatic biopsy diagnosed metastasis
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enrolled in a clinical trial with cisplatinþgemcitabineþHSP90i
(DEBIO0932, NCT01714037) (11). After two cycles, a CT scan
showed partial response, with a 51.5% reduction of target
lesions. After completing six cycles of chemotherapyþHSP90i,
the tumor shrank by 66.5%. After 38 months of treatment, the
patient presented an almost complete response (92.0% reduc-
tion) and still continues with HSP90i monotherapy today.
After 28 months of treatment with HSP90i, the patient was
diagnosed with triple-negative breast cancer, and a right mas-
tectomy with lymph axillar dissection was performed. The pa-
thology exam revealed a 19 mm IDC grade 3 and negative
lymph nodes. No adjuvant treatment was indicated to maintain
the NSCLC therapy with HSP90i.
We sought to understand the unexpected and exquisite sen-
sitivity to chemotherapy plus HSP90i followed by HSP90i
maintenance in this patient. Detailed methods are presented in
the Supplementary Methods (available online). Statistics were
determined by one- or two-way analysis of variance (ANOVA)
with Tukey’s post hoc test (two-sided). A P value of less than .05
was considered statistically significant. After institutional
review board approval and informed consent for a translational
study at our institution, we performed whole-exome sequenc-
ing (WES) of the lung tumor and germline DNA, identifying a
BRCA1/2 deficiency mutational signature but no additional or
actionable driver mutations (Supplementary Table 1, available
online) (12). The patient was referred for germline genetic test-
ing, and the analysis of BRCA1/2 in blood unveiled a pathogenic
heterozygous variant BRCA1 c.527delC (p.176fs) exon 8. WES of
the breast tumor performed at the same point revealed a geneti-
cally different tumor with some coincident mutations
(Supplementary Table 1, available online).
To confirm the exceptional response of chemotherapy plus
HSP90i, we tested whether the combination was more effective
than chemotherapy alone in a platinum-naı̈ve PDX from a
gBRCA1 carrier who had developed breast cancer (PDX127) (13).
Mice were maintained in accordance with local guidelines and
therapeutic interventions approved by the Animal Care and Use
Committees of Vall D’Hebron Institute of Oncology. Animal care
procedures followed recommendations from appropriate com-
mittees. This tumor model does not exhibit BRCA1 foci but is
Figure 1. Tumor sites and therapies timelines. A) In the upper section, timelines of the different tumors and treatments received. In the lower part, morphological ap-
pearance of the first invasive ductal breast carcinoma, lung tumor, and second breast cancer (hematoxylin and eosin, 20); allelic expression of BRCA1 and patterns of
insertions and deletions of indel length distribution in the three tumors through exome sequencing. B) Timing of genotypic analysis performed in different samples
along the evolution of disease. C) Tumor response represented with computed tomography scans of the liver metastasis of non–small cell lung cancer at the time
points indicated: previous systemic treatment, after two cycles of chemotherapy plus HSP90i, at the end of six cycles of chemotherapy, after 12 months with HSP90i, af-
ter 24 months with HSP90, and at 36 months with HSP90i. The scale bars are presented on the left of images, and each small bar represents 2 cm. FEC ¼ fluorouracil,
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able to recruit the HRR marker RAD51 to sites of DNA damage,
and is therefore resistant to PARP inhibition.
Inhibition of HSP90 with AUY922 (n ¼ 5) in PDX127 or admin-
istration of cisplatin/gemcitabine chemotherapy (n ¼ 5) resulted
in progressive disease (mean tumor volume 6SD ¼ 4.18 61.93
mm3 and 3.3161.95 mm3, P ¼ .006 and P < .001, respectively).
The control tumor (vehicle n ¼ 3) grew to 8.3867.07 mm3
(Figure 2). Remarkably, the triple combination resulted in a
complete response (n ¼ 6, 0.065 60.076 mm3, P < .001 with two-
way ANOVA, Tukey’s multiple comparisons test).
Here we report a lung cancer patient harboring a BRCA1 mu-
tation who responded to six cycles of chemotherapy plus
HSP90i, followed by HSP90i maintenance for more than three
years, a longer than expected response when compared with
standard treatment for NSCLC. Beyond downregulation of
BRCA1 and impairing HRR, inhibition of HSP90 may compro-
mise other DNA repair pathways relevant for cisplatin/gemcita-
bine toxicity, including the ICL repair/Fanconi Anemia pathway,
non-homologous end joining (NHEJ), alternative NHEJ, or repli-
cation fork repair (14–18).
Indeed, cell line studies have demonstrated that HSP90i sen-
sitizes BRCA1-mutant cells to DNA-damaging agents (ionizing
radiation, platinum salts, or PARP inhibitors) (14–19). WES in our
patient showed that both the NSCLC and the IDC tumors har-
bored the intact gBRCA1 mutation with associated loss of the
wild-type allele. Recent reports have shown expression of
BRCA1 hypomorphic isoforms conferring treatment resistance
to platinum salts and PARP inhibitors in BRCA1-mutated tumors
(20,21). Some BRCA1 isoforms rely on HSP90 for their stability.
However, no functional BRCA1 isoform or RAD51 foci was
detected in the patient by immunofluorescence, suggesting that
the activity of HSP90i was independent of BRCA1 isoform stabi-
lization (Figure 2; Supplementary Methods, available online).
We further attempted to decipher the BRCA1-independent
mechanism of action of this combination in PDX127. We postu-
lated that HSP90i downmodulated homologous recombination
(HR) downstream of BRCA1 or ICL repair, two major pathways
involved in DNA repair after platinum plus gemcitabine treat-
ment. To this end, we measured RAD51 and FANC2 foci forma-
tion after treatment, respectively (Supplementary Methods and
Supplementary Figure 2, available online). Surprisingly, neither
HR nor ICL repair was downmodulated by HSP90i in addition to
chemotherapy in vivo, thus indicating that other pathways may
be involved. The specific mechanism of this combination might
A  B 
2way ANOVA  
(Tukey's mulple comparisons test) 
Summary  
p value 
Vehicle vs. AUY922 30mg/kg 0.006 
Vehicle vs. Cis/Gem <0.001 
Vehicle vs. Cis/Gem + AUY922 <0.001 
AUY922 30mg/kg vs. Cis/Gem 0.85 
AUY922 30mg/kg vs. Cis/Gem + AUY922 <0.001 
Cis/Gem vs. Cis/Gem + AUY922 0.01 
Figure 2. Antitumor activity of HSP90i in vivo. Mice were maintained in accordance with local guidelines, and therapeutic interventions were approved by the Animal
Care and Use Committees of Vall dHebron Institute of Oncology. A tumor fragment from the germline BRCA1 PDX127 TNBC model was implanted subcutaneously onto
the flank of six-week-old female nude mice. Mice were supplemented with 1 mmol/L estradiol (Sigma) in the drinking water. A) Immunofluorescence of gH2AX (DNA
DSB marker), BRCA1, or RAD51 (HRR marker) costained with geminin (as marker of the S/G2 phase of the cell cycle). Nuclear foci of gH2AX, BRCA1, and RAD51 are
shown in red; geminin pan-nuclear staining is shown in green. DAPI staining is shown in blue. Three thin sections of formalin-fixed, paraffin-embedded archival sam-
ples of the breast and lung tumors of the patient were stained parallel to sections of PDX127 and a BRCA1 wild-type tumor (Ctþ), which was used as positive control for
all markers. The scale bar represents 5 mm. B) PDX127 was subcutaneously implanted in NMRI mice (vehicle n ¼ 3, HSP90i n ¼ 5, cisplatin plus gemcitabine n ¼ 5, cis-
platin plus gemcitabine plus HSP90i n ¼ 6), and when tumors reached an average size of 200 mm3, mice were treated with vehicle, NVP-AUY922 (mg/kg six days/wk by
oral gavage), cisplatin (6 mg/kg, intravenously [i.v.]) plus gemcitabine (6 mg/kg, i.v.) at the indicated time points (#), or the combination of the three agents. Tumors
were measured by caliper twice weekly. Average (SD) tumor volumes on day 23 were vehicle 8.38 (7.07) mm3, HSP90i 4.18 (1.93) mm3, cisplatin plus gemcitabine
3.31 (1.95) mm3, cisplatin plus gemcitabine plus HSP90i 0.065 (0.076) mm3. Error bars indicate SD. P values using two-way analysis of variance with Tukey’s post hoc
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therefore imply that there are other DNA repair pathways that
BRCA1-deficient cells rely on.
This report raises several points. First, the study of such ex-
traordinary responses in cancer patients could lead to be identi-
fication of mechanisms of sensitivity to novel therapies. We
reported an exceptional response in the context of BRCA-related
tumors. Second, our data support the antitumor activity of
HSP90i in BRCA1-deficient tumors, as previously suggested in
experimental models (14,19). Third, the patient was diagnosed
with an IDC while being treated with maintenance therapy
based on HSP90i. This observation indicates that the evolution of
breast carcinoma with the continuous inhibition of HSP90 might
have been less reliant on NHEJ for survival and therefore insensi-
tive due to the lengthy inhibition of HSP90 monotherapy. The re-
cent demonstration that HSP90 can modify environment
susceptibility in genetic diseases reinforces our observation (22).
A limitation to our study is the absence of a PDX model with
the tumor tissue of the patient due to the complete response.
We therefore intended to extend our clinical observation into a
PDX that closely recapitulates the BRCA1 status and clinical his-
tory of the reported patient.
Our results suggest that tumors with BRCA1 alterations may
benefit from adding HSP90i to chemotherapy, suggesting the
use of HSP90i-based therapy in patients with BRCA-related
tumors or a BRCA-ness phenotype. Our model could have impli-
cations for the future development of HSP90i-based therapies
against BRCA-related cancers.
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